Zhenya Lindgardt Sells 27,997 Shares of Sera Prognostics, Inc. (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERAGet Free Report) CEO Zhenya Lindgardt sold 27,997 shares of Sera Prognostics stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $224,815.91. Following the sale, the chief executive officer now directly owns 947,003 shares in the company, valued at $7,604,434.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sera Prognostics Trading Down 4.7 %

NASDAQ SERA opened at $7.92 on Thursday. The company has a fifty day moving average price of $5.78 and a 200-day moving average price of $3.33. Sera Prognostics, Inc. has a 1 year low of $1.15 and a 1 year high of $9.86.

Sera Prognostics (NASDAQ:SERAGet Free Report) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.07. Sera Prognostics had a negative net margin of 11,534.24% and a negative return on equity of 44.04%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Equities research analysts forecast that Sera Prognostics, Inc. will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Sera Prognostics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SERA. CWM LLC bought a new position in Sera Prognostics during the fourth quarter valued at approximately $242,000. Perigon Wealth Management LLC purchased a new position in shares of Sera Prognostics in the fourth quarter worth about $509,000. Vanderbilt University bought a new stake in shares of Sera Prognostics in the 4th quarter valued at about $284,000. Resource Consulting Group Inc. purchased a new stake in Sera Prognostics during the 4th quarter valued at about $265,000. Finally, Vanguard Group Inc. boosted its stake in shares of Sera Prognostics by 1.7% during the third quarter. Vanguard Group Inc. now owns 786,792 shares of the company’s stock valued at $1,463,000 after purchasing an additional 13,364 shares during the period. 30.46% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, William Blair reissued an “outperform” rating on shares of Sera Prognostics in a research report on Thursday, November 9th.

Read Our Latest Stock Report on SERA

About Sera Prognostics

(Get Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.

Further Reading

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.